ASCO® 2021

Presentations

SGN-B6A | Solid Tumors | Abstract TPS3144

A Phase 1 Study of SGN-B6A, an Antibody-Drug Conjugate Targeting Integrin Beta-6, in Patients With Advanced Solid Tumors (SGNB6A-001, Trial in Progress)